|Description||Novobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the interaction of both p23 and Hsp70 co-chaperones with the Hsp90 complex.IC50 700μmol/L|
|Brife Description||Novobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90. IC50 700μmol/L.|
|Storage||3 years -20oC powder, 6 months-80oC in solvent.|
PU-WS13 is a cell-permeable inhibitor of Grp94 (EC50 = 220 nM).It shows selectivity for Grp94 over the related Hsps Trap-1, Hsp90α, and Hsp90β. PU-WS13 blocks t...
17-AAG hydrochloride is a potent HSP90 inhibitor with IC50 value of 5 nM, which is a 100-fold higher binding affinity for HSP90 derived from tumour cells than t...
XL888 is an ATP-competitive inhibitor of Hsp90. Through this action, specific client proteins are degraded, leading to cell cycle arrest or apoptosis. XL888 is ...
Triolimus is a composed of a micelle containing the drugs rapamycin, 17-AAG, and paclitaxel, which act synergistically to inhibit tumor growth
CH5138303 is a novel and potent Hsp90 inhibitor. CH5138303 showed high binding affinity for N-terminal Hsp90α (Kd=0.52nM) and strong in vitro cell growth inhibi...
Radester is a hybrid composed of radicicol's resorcinol and geldanamycin’s benzoquinone part structures and exhibits good cellular activity against MCF7 breast ...
SNX-7081 is a novel small molecule inhibitor of Hsp90. SNX-7081 showed strong binding affinity to Hsp90 and expected induction of Hsp70. NF-kappaB nuclear trans...
KF25706 is derivative of radicicol, binds to the Hsp90 chaperone machinery, IC50 39nM.
BIIB021 is An orally active, purine-scaffold, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. BIIB021 that is ...
KW-2478 is an agent that targets the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be ...
Pochocin A is a patent Hsp90 inhibitor. IC50 90nM.
NW-457 is a potent Hsp90 inhibitor with no detectable hepatocytotoxicity in vitro. It synergizes with ionizing irradiation to induce chromatin condensation, nuc...
NVP-BEP800 is a novel, fully synthetic Hsp90β inhibitor with IC50 of 58 nM, exhibits >70-fold selectivity against Hsp90 family members Grp94 and Trap-1.
17-AAG is an orally bioavailable, small-molecule inhibitor of several receptor protein tyrosine kinases with potential antiangiogenic and antineoplastic activit...
SH-1242 is an analog of deguelin that binds the C-terminus of Hsp90 and inhibits its function, resulting in decreased tumor cell growth.
An orally bioavailable formulation of the ansamycin derivative 17-amino-17-demethoxygeldanamycin (17-AG) with potential antineoplastic activity. Oral Hsp90 inhi...
Onalespib, also known as AT13387, is a synthetic, orally bioavailable, small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic a...
Hsp980 is an orally bioavailable inhibitor of human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Hsp980 binds to and inhibits the acti...
VER-50589 is a potent Hsp90 inhibitor with IC50 of 21 nM for Hsp90β.
NMS-E973 shows a widespread antiproliferative activity with an average IC50 of 1.6 μM, and induces the degradation of client protein.